Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $500.00 | 18 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $240.19 | 2 | $0 (2019) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $204.70 | 13 | $0 (2024) |
| Melinta Therapeutics, LLC | $22.14 | 1 | $0 (2023) |
| Paratek Pharmaceuticals, Inc. | $19.84 | 1 | $0 (2022) |
| Alnylam Pharmaceuticals Inc. | $13.13 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $21.43 | 1 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($21.43) |
| 2023 | $22.14 | 1 | Melinta Therapeutics, LLC ($22.14) |
| 2022 | $182.11 | 12 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($149.14) |
| 2021 | $34.13 | 2 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($34.13) |
| 2019 | $121.77 | 1 | Alexion Pharmaceuticals, Inc. ($121.77) |
| 2018 | $118.42 | 1 | Alexion Pharmaceuticals, Inc. ($118.42) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.43 | General |
| Category: Gastroenterology | ||||||
| 10/06/2023 | Melinta Therapeutics, LLC | Rezzayo (Drug), Kimyrsa, Vabomere | Food and Beverage | In-kind items and services | $22.14 | General |
| Category: ANTIFUNGALS | ||||||
| 12/01/2022 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $13.13 | General |
| Category: Genetic Disease | ||||||
| 11/30/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.00 | General |
| Category: Gastroenterology | ||||||
| 11/18/2022 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: ANTIBIOTIC | ||||||
| 11/16/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: Gastroenterology | ||||||
| 06/22/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $9.58 | General |
| Category: Gastroenterology | ||||||
| 05/25/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $9.79 | General |
| Category: Gastroenterology | ||||||
| 05/25/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $3.78 | General |
| Category: Gastroenterology | ||||||
| 04/27/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.28 | General |
| Category: Gastroenterology | ||||||
| 03/30/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: Gastroenterology | ||||||
| 03/23/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: Gastroenterology | ||||||
| 03/16/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Gastroenterology | ||||||
| 02/01/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.17 | General |
| Category: Gastroenterology | ||||||
| 12/20/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $12.76 | General |
| Category: Gastroenterology | ||||||
| 12/15/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: Gastroenterology | ||||||
| 06/27/2019 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Food and Beverage | In-kind items and services | $121.77 | General |
| Category: Immunology | ||||||
| 02/27/2018 | Alexion Pharmaceuticals, Inc. | SOLIRIS (Drug) | Food and Beverage | In-kind items and services | $118.42 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 247 | 687 | $333,474 | $91,304 |
| 2022 | 6 | 338 | 994 | $467,050 | $125,035 |
| 2021 | 5 | 309 | 894 | $380,045 | $101,524 |
| 2020 | 7 | 295 | 817 | $285,994 | $71,876 |
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 160 | 296 | $166,944 | $46,725 | 28.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 59 | 361 | $143,317 | $39,955 | 27.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 28 | 30 | $23,213 | $4,625 | 19.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 158 | 310 | $174,840 | $53,162 | 30.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 70 | 533 | $211,601 | $51,584 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 50 | 89 | $37,469 | $9,429 | 25.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 24 | 24 | $19,484 | $5,184 | 26.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 22 | 24 | $12,792 | $3,058 | 23.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $10,864 | $2,619 | 24.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 58 | 411 | $163,167 | $40,116 | 24.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 114 | 273 | $114,933 | $33,162 | 28.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 80 | 109 | $61,476 | $18,565 | 30.2% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 39 | 49 | $26,117 | $6,199 | 23.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 18 | 52 | $14,352 | $3,483 | 24.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 57 | 373 | $99,384 | $24,587 | 24.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 106 | 207 | $83,573 | $20,122 | 24.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 34 | 126 | $48,747 | $11,976 | 24.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 36 | 46 | $23,770 | $5,924 | 24.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 28 | 29 | $15,573 | $4,063 | 26.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 15 | 16 | $12,000 | $3,099 | 25.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 19 | 20 | $2,947 | $2,105 | 71.4% |
About Dr. Nandita Singh, D.O
Dr. Nandita Singh, D.O is a Internal Medicine healthcare provider based in Valhalla, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/29/2007. The National Provider Identifier (NPI) number assigned to this provider is 1912108937.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nandita Singh, D.O has received a total of $500.00 in payments from pharmaceutical and medical device companies, with $21.43 received in 2024. These payments were reported across 18 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($500.00).
As a Medicare-enrolled provider, Singh has provided services to 1,189 Medicare beneficiaries, totaling 3,392 services with total Medicare billing of $389,740. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Nephrology
- Location Valhalla, NY
- Active Since 05/29/2007
- Last Updated 02/22/2021
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1912108937
Products in Payments
- SOLIRIS (Drug) $240.19
- XIFAXAN (Drug) $204.70
- Rezzayo (Drug) $22.14
- NUZYRA (Drug) $19.84
- GIVLAARI (Drug) $13.13
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Valhalla
Dr. Jay Doshi, M.d, M.D
Internal Medicine — Payments: $96,684
Luciano De Marco, M.d, M.D
Internal Medicine — Payments: $14,149
Neal Shah, M.d, M.D
Internal Medicine — Payments: $5,403
Sade Solola Nussbaum, Md, MD
Internal Medicine — Payments: $4,024
Rhonda Rubin, Md, MD
Internal Medicine — Payments: $2,982
Adrese Kandahari, M.d, M.D
Internal Medicine — Payments: $2,880